Annovis Bio Inc

Annovis Bio Insider Rush: CEO Michael Hoffman Buys 2.4M Shares Ahead of $1.9M IPO, Betting on Alzheimer’s Breakthroughs

Insider buying spurs confidence in Annovis Bio’s Alzheimer’s pipeline as Hoffman tops 2.4 M shares ahead of a $1.9 M IPO, signaling potential upside.

Annovis Bio Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

22/05/2026, 02:26

3 minutes to read

Director Hoffman Ramps Up Annovis Shares, Buying 714K Amid Volatile Price Surge

Hoffman’s recent 713,800‑share buy at $2.10 shows renewed confidence in Annovis Bio’s buntanetap pipeline, offering a bullish outlook amid volatile stock price.

Annovis Bio Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

03/04/2026, 23:22

3 minutes to read